Oral medicines avoid injections, but some require daily dosing and fasting rules. Injectable products may be used daily or weekly and require device training and appropriate storage. Formulation alone does not rank effectiveness or safety.
Compare the practical demands of each formulation
Oral-product examples here use US prescribing information. They do not establish South Korean approval, launch or availability. Confirm locally available products with your clinician or pharmacist.
| Consideration | Oral medicine | Injection |
|---|---|---|
| Administration | Swallow a tablet | Subcutaneous injection and pen handling |
| Schedule | US oral examples here are once daily [1][2] | Saxenda daily; Wegovy and Mounjaro weekly [3][4][5] |
| Convenience | No needle, but daily instructions to remember | Weekly products need fewer administrations, but require pen and storage management |
| Food conditions | Some require fasting and a waiting period [1] | Check product-specific timing and food instructions |
| Selection factors | Approved purpose, dosing conditions and other oral medicines | Approved purpose, device handling and storage circumstances |
Not all oral medicines have the same instructions
US RYBELSUS / OZEMPIC tablet instructions specify morning use on an empty stomach with no more than about 120 mL of water. Wait at least 30 minutes before food, drinks or other oral medicines. Swallow whole rather than splitting or chewing.[1]
US FOUNDAYO (orforglipron), a different oral GLP-1 receptor agonist, can be taken with or without food.[2] Do not assume that every oral GLP-1 medicine requires fasting.
Convenience depends on your routine
Someone uncomfortable with needles may prefer to discuss an oral option. However, a fasting requirement can be difficult if breakfast or other medication times vary. A weekly schedule has fewer doses to remember but still needs a reliable record of the last administration.
For frequent travel, ask about storage, transport and time zones. Check actual cost and availability too. Compare the options that can appropriately be prescribed for you, not just the formulation that initially seems easiest.
Are tablets weak and injections strong?
That conclusion cannot be drawn from formulation alone. Meaningful comparisons need the ingredient, dose, treatment goal, study population and observation period. Placing weight-loss percentages from separate trials side by side does not create a like-for-like comparison.
Oral products are prescription medicines with gastrointestinal adverse effects and other precautions.[1][2] Do not independently convert milligrams when switching formulations or ingredients; ask your prescriber how a change should be made.
Distinguish 'liquid GLP-1' advertising from prescription medicine
A 'GLP-1' marketing term or liquid form does not establish an approved oral medicine. Check the ingredient, strength, local indication and official leaflet. FDA describes safety, effectiveness and quality concerns about unapproved GLP-1 products. This is US guidance; other countries' approvals must be checked separately.[6]
A small check-in today
- Have you distinguished local information from overseas examples?
- Have you checked your exact product’s food and dosing conditions?
- Can you describe your routine and storage circumstances at your visit?
Frequently asked questions
Must all oral GLP-1 medicines be taken fasting?
No. It depends on the ingredient and product. Do not transfer the fasting rules of certain oral semaglutide products to every oral medicine.
Can I replace an injection with a tablet containing the same milligrams?
No. Dose systems differ by formulation and ingredient. Do not calculate a substitution independently.
Does a liquid GLP-1 product work like a tablet?
A marketing name or formulation cannot establish equal effects. Do not apply prescription-tablet evidence here to a liquid or supplement whose ingredients and approval are unverified.
The GLP1 Helper editorial team prepared this general information from public sources. It has not received individual medical-expert review. It does not replace diagnosis or prescribing. Confirm approved uses and instructions in your country with your prescriber or pharmacist. Editorial principles
References
- Novo Nordisk · RYBELSUS / OZEMPIC tablets prescribing informationUS approved information · oral semaglutide · Source checked 2026-10-07
- Lilly · FOUNDAYO (orforglipron) prescribing informationUS approved information · oral orforglipron · Source checked 2026-10-07
- MFDS · Saxenda pen product informationSouth Korean approved information · adult dosing · Source checked 2026-10-02
- MFDS · Wegovy prefilled pen product informationSouth Korean approved information · adult dosing · Source checked 2026-10-02
- Lilly Korea · Mounjaro frequently asked questionsSouth Korean manufacturer · product information · Source checked 2026-10-07
- FDA · Unapproved GLP-1 productsUS FDA · compounded-medicine safety information · Source checked 2026-10-07